Plus Therapeutics Appoints Diagnostics Veteran Ron Andrews To Board Of Directors, Bringing Decades Of Diagnostics Leadership

Plus Therapeutics, Inc. has announced the appointment of Ron Andrews to its Board of Directors. The move brings extensive leadership experience in diagnostics and molecular diagnostics to the company as it continues advancing precision diagnostics and radiopharmaceuticals for central nervous system cancers.

“Ron Andrews brings an extensive wealth of diagnostics experience to the Plus board room developed over multiple decades in the industry,” said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. “He will make an immediate impact on the Company as we scale CNSide, first in the U.S. and then globally. Furthermore, his breadth of connections throughout the global diagnostics industry will help the Company maximise the positive impact of CNSide on patients with central nervous system cancers and drive value for stockholders.”

Mr. Andrews brings more than 35 years of experience, having held leadership roles across major organisations such as Abbott Diagnostics, Roche Molecular Diagnostics, and Thermo Fisher Scientific, as well as serving as CEO of companies like Clarient Inc. and Oncocyte Inc.. More recently, he has supported venture-backed firms in executive roles, helping guide product development and fundraising efforts.

Mr. Andrews added, “CNSide represents an important leap forward in technology, utilising cerebrospinal fluid to help physicians better identify and manage leptomeningeal metastases. I’m pleased to join Plus’s board and to work closely with my fellow board members and management to optimise its strategy and path forward in its diagnostics business.”

Throughout his career, Andrews has contributed to raising over $600 million in capital and has played a role in exits totalling more than $15 billion. He has also served on multiple public and private boards, including CancerLinQ LLC, a joint venture of the American Society of Clinical Oncology, and continues to serve on various boards in the molecular diagnostics space.